Cambridge Healthtech Associates™ Announces arGEN-X as Inaugural Signature Award™ Winner

Share Article

Signature Award recognizes life sciences companies developing unique technologies

News Image

(PRWEB) May 14, 2012 -- Cambridge Healthtech Associates™ (CHA™) today announced that arGEN-X is the winner of its inaugural Signature Award™.

The Signature Award honors organizations with promising biotechnologies, judged on the following criteria: 1) well-differentiated value proposition to the marketplace and 2) market or partner readiness. arGEN-X competed with 38 emerging companies for this prestigious award.

“We recognize that the ‘science’ of health care is getting harder, and not easier. So at Cambridge Healthtech Associates, we would like to highlight the accomplishments of some true leaders and pioneers in the industry. To this end, we have created the Signature Award™ to profile and share with the life sciences discovery community some truly innovative technologies and solutions that are ready to take the market by storm. We are pleased to shine the light on arGEN-X, its innovation-driven culture and its clearly differentiated antibody discovery capabilities. As a pioneer in providing therapeutic-quality antibodies against the most challenging disease targets in our industry, arGEN-X meets the criteria we have set for the Signature Award™,” said Dawn Van Dam, General Manager, Cambridge Healthtech Associates.

“We are delighted to win the Signature Award for our antibody discovery technologies, the source of an exciting preclinical product pipeline which we have developed in less than four years. Our uniqueness comes from our SIMPLE Antibody™ platform: human antibodies of unlimited functional diversity and novel mechanisms of action against even highly complex disease targets. We are recognized in the industry for addressing needs beyond the reach of established antibody technologies,” said Dr. Debbie Allen, Senior Director of Business Development at arGEN-X.

As a winner of this award, arGEN-X receives a complimentary thought leadership webinar in conjunction with one of CHA’s online communities – The Drug Safety Executive Council™ or NGS Leaders™.

Cambridge Healthtech Associates™ (CHA™) uses its unique collaborative model to improve the speed, economics and effectiveness of life science research and development, leveraging its consulting, technology evaluations and communities to help clients in the industry achieve their individual goals. Read more at

Cambridge Healthtech Associates organizes two online communities: NGS Leaders™ ( is an online community for people working in next-generation sequencing, genomics, bioinformatics and the Drug Safety Executive Council™ (, an online community focused on the development of better and safer medicines.

About arGEN-X
arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging the power of its broadly applicable, proprietary SIMPLE Antibody™ platform to generate fully human antibodies with differentiated qualities and outstanding therapeutic potential. The platform excels in delivering large panels of ultra-potent, functionally diverse antibodies against complex disease targets, especially cell surface receptors and highly conserved proteins.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alison Serrano

Debbie Allen, Senior Director of Business Development
+44 7974 979479
Email >
Visit website